2013
DOI: 10.1002/acn3.17
|View full text |Cite
|
Sign up to set email alerts
|

The role of ventriculoperitoneal shunting in patients with supratentorial glioma

Abstract: ObjectivesTo assess the impact of ventriculoperitoneal (VPS) in patients with glioma.MethodsRetrospective review of patients with grade II-IV glioma who had VPS placement from January 1995 to November 2012.ResultsWe identified 62 patients. At time of VPS, 41 had gait disturbance, 40 cognitive impairment and 16 urinary incontinence; 10 had the classic triad. Thirty-eight (61%) improved after VPS. Median overall survival from VPS was 7 months for all patients, but 11 months for those who improved and 2 months fo… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

0
4
0

Year Published

2016
2016
2022
2022

Publication Types

Select...
5
3

Relationship

1
7

Authors

Journals

citations
Cited by 14 publications
(4 citation statements)
references
References 13 publications
0
4
0
Order By: Relevance
“…De la Fuente analysed 62 patients with supratentorial glioma, of which 41 had glioblastoma. Among these patients, 27% had complications related to ventriculoperitoneal shunts [ 12 ]. Further, a more recent study reported that shunt complications required surgical revision in 4 of 12 (33%) high-grade glioma patients with ventriculo-/cystoperitoneal shunts [ 34 ].…”
Section: Discussionmentioning
confidence: 99%
“…De la Fuente analysed 62 patients with supratentorial glioma, of which 41 had glioblastoma. Among these patients, 27% had complications related to ventriculoperitoneal shunts [ 12 ]. Further, a more recent study reported that shunt complications required surgical revision in 4 of 12 (33%) high-grade glioma patients with ventriculo-/cystoperitoneal shunts [ 34 ].…”
Section: Discussionmentioning
confidence: 99%
“…Placing a VPS in patients with LMD may be followed by radiation to symptomatic areas, treatment with systemic BBB‐penetrating chemotherapy (e.g. methotrexate and cytarabine) and, potentially, intrathecal chemotherapy in patients without bulky leptomeningeal disease and significant hydrocephalus (Clarke, ; de la Fuente & DeAngelis, ). Intrathecal chemotherapy may not be appropriate in a patient with overt hydrocephalus because of a risk for necrotizing leucoencephalopathy (Omuro et al , ; Lin & Avila, ).…”
Section: Elevated Intracranial Pressurementioning
confidence: 99%
“…When the process is sufficiently indolent, the ventricles may enlarge without increasing the opening pressure. 34 This latter group develops symptoms of normal pressure hydrocephalus, that is, apraxic gait, incontinence, and progressive confusion. 1 Other signs and symptoms of leptomeningeal carcinomatosis that co-occur with hydrocephalus, which help to make the diagnosis, include CN palsies, radiculopathy, nuchal rigidity, and cortical deficits.…”
Section: Hydrocephalusmentioning
confidence: 99%
“…While an improvement in neurologic symptoms following a high-volume CSF drainage suggests that the patient will benefit from a ventriculoperitoneal shunt, patients with large ventricles, with the right clinical phenotype, may benefit from a ventriculoperitoneal shunt in spite of a negative tap test. 34 Placing a ventriculoperitoneal shunt in patients with leptomeningeal disease may be followed by radiation to symptomatic areas, treatment with systemic chemotherapy with good blood-brain barrier penetration, and potentially intrathecal chemotherapy in patients who do not have bulky leptomeningeal disease and without significant hydrocephalus. 35 Intrathecal chemotherapy may not be appropriate in a patient with overt hydrocephalus because it is a risk factor for the development of a necrotizing leukoencephalopathy.…”
Section: Hydrocephalusmentioning
confidence: 99%